Solara Active Pharma Sciences Past Earnings Performance
Past criteria checks 0/6
Solara Active Pharma Sciences's earnings have been declining at an average annual rate of -52.9%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 0.02% per year.
Key information
-52.9%
Earnings growth rate
-65.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -0.02% |
| Return on equity | -21.0% |
| Net Margin | -21.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Solara Active Pharma Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 14,069 | -3,083 | 2,503 | 0 |
| 30 Sep 23 | 15,529 | -325 | 2,461 | 0 |
| 30 Jun 23 | 14,661 | -253 | 2,359 | 0 |
| 31 Mar 23 | 14,438 | -222 | 2,308 | 0 |
| 31 Dec 22 | 14,240 | -241 | 2,150 | 0 |
| 30 Sep 22 | 11,296 | -1,644 | 2,221 | 0 |
| 30 Jun 22 | 11,928 | -1,247 | 2,319 | 0 |
| 31 Mar 22 | 12,683 | -581 | 2,392 | 0 |
| 31 Dec 21 | 13,517 | -34 | 2,529 | 0 |
| 30 Sep 21 | 16,781 | 2,023 | 2,472 | 0 |
| 30 Jun 21 | 16,740 | 2,293 | 2,393 | 0 |
| 31 Mar 21 | 16,169 | 2,214 | 2,327 | 0 |
| 31 Dec 20 | 14,694 | 1,826 | 2,297 | 0 |
| 30 Sep 20 | 13,864 | 1,581 | 2,212 | 0 |
| 30 Jun 20 | 13,400 | 1,304 | 2,139 | 0 |
| 31 Mar 20 | 13,218 | 1,146 | 2,080 | 0 |
| 31 Dec 19 | 14,103 | 1,231 | 2,059 | 0 |
| 30 Sep 19 | 14,228 | 1,039 | 2,032 | 0 |
| 30 Jun 19 | 14,140 | 845 | 1,986 | 0 |
| 31 Mar 19 | 13,867 | 614 | 1,927 | 0 |
| 31 Mar 18 | 5,210 | 60 | 710 | 0 |
Quality Earnings: 541540 is currently unprofitable.
Growing Profit Margin: 541540 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 541540 is unprofitable, and losses have increased over the past 5 years at a rate of 52.9% per year.
Accelerating Growth: Unable to compare 541540's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 541540 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 541540 has a negative Return on Equity (-20.99%), as it is currently unprofitable.